Search

Displaying results 941 - 950 of 7536 in total
  1. Drug

    Methionine

    go.drugbank.com/drugs/DB00134
    ApprovedInvestigationalNutraceutical

    A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.

    Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%
  2. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    Etorphine is only available to the patients under an official prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    [A178579] Sotalol was first approved as an oral tablet on 30 October 1992.

    Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and ThiazidesProducts: Co Sotalol
  4. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids.

  5. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … of metastatic RET-fusion positive non-small cell lung cancer.

  6. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … It presents selectivity against the mutant forms of EGFR compared to the wild-type.

  7. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655]. … Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].

  8. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.

  9. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Factor VIII, but does not contain the B-domain, which has no known biological function and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared … Other drug products with similar structure and function to Antihemophilic factor human include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced

  10. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    [L31453] Ivermectin is mainly used in humans in the treatment of onchocerciasis, but may also be effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis … [L31453] Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de

    Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbsProducts: I-Dectin 0.5 % Pour-On, Vimectin 0.5% w/v Pour On